Uncategorized
Indiana Emerges as a Leading U.S. Biopharma Hub
Sponsored content brought to you by
The next generation of leading life science regions will not be defined by scientific discovery alone. Their advantage and impact will come from the ability to move promising ideas through development, manufacturing, commercialization, and delivery.
Indiana has spent decades building those capabilities, becoming a national leader in life sciences and pharmaceutical exports. Its strengths extend across universities, research institutes, manufacturers, suppliers, healthcare systems, and communities throughout the state. Together, they form a strategically connected ecosystem with the breadth, depth, and scale to support innovation at every stage and move products from the lab to patients worldwide. That proximity matters. When intellectual property timelines are ticking, speed to market is critical.
Indiana’s rising national position is driven not by one company, institution, or scientific specialty, but by the concentration and connectivity of capabilities across the state. Those strengths span human and health, animal health, and plant science, which share common functions across the value chain. In human health, Indiana has deep capabilities in large- and small-molecule discovery and manufacturing, medical devices and diagnostics, and clinical research and testing. That breadth creates partnering opportunities as ideas advance.
A discovery may begin at a university, move through clinical development and regulatory review, draw on specialized manufacturing expertise, and ultimately reach patients through global supply chains. Each capability is important on its own. Together, they create an integrated ecosystem for turning science into impact and expanding opportunity for the more than 70,000 people employed in life sciences statewide.
That collaborative model is becoming increasingly important. Scientific advances are moving faster, development pathways are becoming more complex, and companies need access to specialized talent, infrastructure, capital, and partners at every stage. Indiana is applying its established strengths to areas shaping the next generation of life sciences, including artificial intelligence and computational medicine, radiopharmaceuticals, diagnostics, precision medicine, and advanced pharmaceutical manufacturing.
Indiana also has significant momentum. In 2025, the state’s life sciences sector surpassed $100 billion in economic activity. Indiana is home to Eli Lilly and Company, the world’s highest-valued life sciences company, accounted for one in five life sciences M&A transactions during the first half of 2026.
In 2023, Indiana was designated a federal Tech Hub for biomanufacturing and received a $51 million Economic Development Administration grant, including support for a new biomanufacturing workforce training facility at 16 Tech Innovation District. Lilly Endowment awarded $70 million to establish a fund to attract leading researchers to Indiana University, Purdue University, the University of Notre Dame, and Rose-Hulman Institute of Technology. A coalition led by Indiana University also secured a National Science Foundation Engines award to accelerate innovation in musculoskeletal health and build on Indiana’s position as home to the Orthopedic Capital of the World.
The governor has announced a $1 billion, 10-year investment to grow the biosciences sector in Central Indiana. Indiana is also building on assets in radiopharmaceuticals, where global companies, specialized suppliers, and Purdue University’s leading nuclear medicine program support the development and manufacturing of innovative cancer therapies.
Despite these strengths, Indiana has not consistently told its story. BioHeartland Indiana was launched to elevate awareness of the state’s capabilities and clearly express its ambition to expand its leadership in biosciences.
What has been built here is more than a strong life sciences sector. It is an environment where ideas can find partners, companies can find the resources to grow, and products can move from discovery to patients and markets.
For investors seeking compelling inventions, researchers looking for clinical partners, and companies deciding where to expand, Indiana offers a rare combination: the capacity to invent, the infrastructure to make, and the networks to move life sciences products at scale.

To learn more, visit www.inbioheartland.com.
The post Indiana Emerges as a Leading U.S. Biopharma Hub appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.
You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.
Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.
Q&A with the speakers follows the presentations.
The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).
Uncategorized
Psilocybin proves promising in neuropathic pain mouse study
Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
Uncategorized
New Spectrometry Technique Could Aid Formulation Development
New Spectrometry Technique Could Aid Formulation Development
A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.
According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.
“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”
Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.
The challenge is understanding the link between these things within a heterogeneous sample, he says.
To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.
He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.
Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.
Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Uncategorized8 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized7 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized6 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized6 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Fierce Biotech8 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Nature Biotechnology8 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read
